Boston— Boston has reasserted itself as the nation’s dominant life sciences market, signaling a potential turning point after two cautious years for the sector, according to the latest H2 U.S. Life Sciences report from Avison Young.
The report finds that Boston, alongside the Bay Area, is once again driving U.S. life sciences leasing activity, returning to its traditional leadership position after a slowdown in 2023 and 2024. Together, the two markets accounted for roughly 50% of national leasing activity, marking a significant rebound from the prior year. When measured more broadly, Boston and the Bay Area captured approximately 70% of total lab leasing demand in 2025, underscoring what the report describes as a “flight-to-core” trend among tenants seeking established ecosystems with deep talent pools and access to research institutions and capital.
Leasing Momentum Returns — But Below Historic Norms
According to Avison Young, leasing activity across all major U.S. life sciences markets remained below pre-pandemic annual averages (2015–2019) in 2025, reflecting a still-cautious expansion environment among biotech and pharmaceutical occupiers. Even so, 2025 marked the strongest year for leasing demand since 2022, with more than 3 million square feet of lab and R&D transactions completed nationwide.
Boston posted one of the strongest leasing recoveries among U.S. lab hubs. A renewed influx of venture capital into Greater Boston-based life sciences firms, combined with several high-profile expansions and portfolio consolidations, helped stabilize market conditions. Availability rates began to level off for the first time in the current cycle.
Tucker White, U.S. Life Science Lead, Market Intelligence at Avison Young, said the market is offering tenants rare advantages.
“The current environment is creating a rare window where companies can secure premier lab space in Boston with more flexibility and better economics than we’ve seen in years,” White said. “That dynamic is already translating into renewed leasing velocity.”
Capital Flows Strengthen Innovation Pipeline
The recovery in leasing coincided with a resurgence in biotech funding. According to the report, 2025 delivered the strongest year for venture capital investment in the sector since 2021. Funding remained highly concentrated, with Boston- and San Diego-based companies capturing approximately 66% of total VC dollars.
While most capital targeted Series A and B rounds, reflecting investor preference for more de-risked platforms, the report also notes a rebound in seed and pre-funding activity. This early-stage uptick suggests accelerating company formation and a rebuilding innovation pipeline — a key driver of future lab space demand.
Elevated Supply Creates Tenant Advantage
Despite improving demand, supply pressures remain significant. Greater Boston recorded negative net absorption of 2.86 million square feet in 2025 — the first annual decline since 2011 — driven by large sublease availabilities, tenant footprint consolidations, and, in some cases, company bankruptcies.
As a result, roughly one-third of Boston’s life sciences inventory is currently available for lease, highlighting a pronounced supply-demand imbalance. Similar elevated availability levels persist in other major hubs, including the Bay Area and San Diego, where more than a quarter of inventory remains on the market.
However, this surplus is also creating opportunity. Large blocks of available space are giving tenants unprecedented optionality, accelerating relocations and decision-making. Increased sublease supply is offering discounted entry points for growth-stage biotech firms seeking high-quality space in premier locations.
Development Pipeline Resets
Construction activity has slowed sharply nationwide. After peaking at approximately 13 million square feet in 2022, development fell to just 3.2 million square feet by year-end 2025. No new projects broke ground during the year, reflecting muted demand and elevated construction costs. The slowdown signals a broader reset in the development pipeline and may set the stage for tighter conditions in 2026 as existing inventory is gradually absorbed.
Outlook for 2026
According to Avison Young, overall availability has begun to level off, suggesting the market may be nearing an inflection point. Rising leasing activity combined with limited new supply could gradually tighten conditions next year, particularly if funding momentum continues.
While rent growth is likely to remain subdued in the near term as markets work through excess supply, the report identifies Boston as well-positioned for a stronger 2026. Stabilizing tenant demand, improving capital flows, and favorable lease economics are aligning to support renewed expansion in one of the nation’s most established life sciences ecosystems.
